Overview

Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment

Status:
Completed
Trial end date:
2012-06-22
Target enrollment:
Participant gender:
Summary
This study will assess the safety and pharmacokinetics of inhaled GSK573719 and GSK573719/vilanterol combination in healthy subjects and in subjects with severe renal impairment. The results of the study will provide guidance on the use of this product in subjects with severe renal impairment.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline